Trial
NCT04933617
Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
Burkitt Lymphoma
Intervention
Rituximab
Why stopped
The study was terminated early because copanlisib was removed from the market by the Food and Drug Administration (FDA) and the manufacturer.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-07-09